摘要
目的 通过检测晚期非小细胞肺癌 (NSCLC)患者血清CA12 5 ,以判断血清CA12 5水平对患者预后的影响。方法 6 6例晚期NSCLC患者 ,接受 2～ 4周期化疗 ,其中 17例辅助放疗。所有患者在治疗前抽血测血清CA12 5。结果 2 4例患者血清CA12 5水平升高 ,占 36 4%。CA12 5升高患者的 1年生存率为 12 5 % ,2年生存率为 0 ,与CA12 5正常患者的生存率差异有显著性 (P <0 0 5 )。Cox模型多因素分析表明 ,患者的预后与CA12 5水平 (P =0 0 0 0 )和疗效 (P =0 0 46 )有关。结论 血清CA12 5水平升高的晚期NSCLC患者生存期缩短 ,预后差 ,可以将血清CA12 5水平作为判断晚期NSCLC患者预后的一个独立指标。
Objective To judge the prognostic value of serum CA125 level in patients with advanced non small cell lung cancer. Methods Sixty six untreated patients with advanced non small cell lung cancer (NSCLC) confirmed histologically were studied. They received two to four cycles of chemotherapy, some of them combined with radiotherapy. All these patients were assayed for serum CA125 before treatment. The cut off value of serum CA125 level was 35 U/ml. Results Increased serum CA125 levels were observed in 24 out of 66 patients (36.4%). Patients with increased serum CA125 levels had an average survival rate of 12.5% at 1 year and 0 at 2 years, whereas that of patients with normal serum CA125 levels was of 57.1% at 1 years, 14.3% at 2 years and 7.1% at 3 years. Cox proportion hazard multivariate analysis showed that the prognosis of patients was related to serum CA125 levels ( P =0.000) and effects of treatment ( P =0.046). Conclusion CA125 can be used as an independent prognostic parameter in advanced NSCLC.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2000年第1期30-31,共2页
Chinese Journal of Oncology
关键词
非小细胞肺癌
糖链抗原125
预后
肺癌
Carcinoma, non small cell lung
Carbohydrate antigen 125
Prognosis
